BEIJING & SAN DIEGO--(BUSINESS WIRE)--Annoroad and Illumina, Inc. (NASDAQ: ILMN) today announced they have entered into an agreement to jointly develop advanced clinical applications for reproductive health based on next-generation sequencing (NGS) technology. The collaboration signals the increasing importance of genomic applications to improve healthcare in China.
In recent years, NGS technology has evolved rapidly and is regarded as an essential factor for enabling precision medicine. The collaboration between Annoroad and Illumina will focus on providing the most advanced and integrated sequencing solutions to the clinical market. In particular, the two companies will work together to develop a user-friendly, prenatal DNA diagnostic system for the Chinese market.
The collaboration will bring together technology from Illumina sequencers with Annoroad’s advanced clinical application development capabilities. As part of the agreement, Annoroad will provide its nucleic acid extraction, library preparation, and data analysis software, while Illumina will provide NGS instrument components and related reagents.
"We have been working to promote the clinical application of genomic technology in China. Non-invasive prenatal testing is used widely in the reproductive health arena, and we hope to promote it as a standard practice in hospitals. As one of the first national clinical pilot sites for NGS appointed by the National Health and Family Planning Commission (formerly the Ministry of Health), Annoroad is now very pleased to partner with Illumina, the global leader in sequencing and array technologies. Cooperation between our two companies will provide additional high-quality diagnostic solutions in the field of reproductive health," said Junbin Liang, Annoroad Founder and Chief Executive Officer.
“Illumina is very excited to collaborate with Annoroad to increase access to reproductive health solutions in China,” said Tristan Orpin, Senior Vice President and General Manager of Illumina’s Reproductive and Genetic Health business. “We are committed to partnering with Chinese companies who share our vision of improving human health by unlocking the power of the genome.”
Annoroad is headquartered in Beijing, China and is a well-known enterprise in the genomic industry in China. The company is committed to providing cutting edge genomic solutions in both clinical testing and life science research. Annoroad was entitled as the National High Innovative Technology Enterprise, and charted as the national clinical pilot site of NGS in China given its major position in the domestic market and next-gen sequencing technology. Annoroad has developed serials of NGS diagnostic applications in the field of human reproduction, cancer, and rare diseases, forming the excellent product system and market brand. In the field of science and technology service, Annoroad provides state-of-the-art sequencing and bioinformatics solutions for research organizations under its sub-brand.
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
Forward-Looking Statement for Illumina
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.